Research Article Details
| Article ID: | A25079 |
| PMID: | 22184802 |
| Source: | MMW Fortschr Med |
| Title: | [Omega-3 fatty acids as an option in the treatment of NAFLD]. |
| Abstract: | BACKGROUND: Human tissues or organs vary in the content of long-chain omega-3 fatty acids, in case of diseases the content may even change. These findings cannot be extrapolated from blood lipids. METHODS: Overview RESULTS: By means of liver biopsies it has been shown that eicosapentaenoic acid (EPA) significantly decreases with raising triglyceride accumulation in hepatocytes. This is associated with increased histological signs of inflammation in liver parenchyma. In a study the intake of omega-3 fatty acids (1 g/d) resulted in a rising percentage of EPA in liver triglycerides associated with a reduction of liver fat and inflammation markers. CONCLUSION: From the results a hitherto widely ignored indication for NAFLD with or without metabolic syndrome can be derived. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D258 | Omega 3 PUFA | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Hypolipidemic drug | Under clinical trials | Details |
| D527 | EPA/DHA | Supplement | DB11133 | -- | -- | Under clinical trials | Details |
| D125 | Epanova | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Enhance lipid metabolism | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |